GET THE APP

Seroprevalence of SARS-CoV-2 in Niger State: the Implications of the Findings and COVID-19 Vaccines Choices for the Sub-Sharan Africa | Abstract
Journal of Clinical Trials

Journal of Clinical Trials
Open Access

ISSN: 2167-0870

+44 20 3868 9735

Abstract

Seroprevalence of SARS-CoV-2 in Niger State: the Implications of the Findings and COVID-19 Vaccines Choices for the Sub-Sharan Africa

Hussaini Majiya

The pilot cross sectional seroprevalence of SARS CoV-2 study conducted in Niger State, Nigeria, by June of 2020, reveals high asymptomatic rate of COVID-19 and prevalence of 25.41% despite the lockdown enforced in the State three (3) months prior to the study when the lockdown ended. The observed SARS-CoV-2 seroprevalence and infection patterns means that the virus is widely spread, far more SARS CoV-2 infections occurred than the official reported cases. The study also revealed lack of full compliance to some of the COVID-19 control measures especially the social distancing, even during the lockdown. It is expected that SARS CoV-2 infections will continue in the State with the people either not experiencing symptoms or experiencing mild symptoms in some cases and very low COVID-19 fatality. The information about SARS CoV-2 prevalence, asymptomatic rate and fatality, geography and demography, vaccine hesitancy, myths and disbelief, and availability or lack of power infrastructures and cold chain storage facilities for vaccines, can ultimately determine what type of COVID-19 vaccine that is rolled out in a country or region. This review is focused on the implication of the findings of the study- “Seroprevalence of SARS-CoV-2 in Niger State”. It also highlighted COVID-19 vaccines choices for the Sub-Sharan Africa.

Published Date: 2021-09-20;